During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...
Bristol Myers Squibb & Co (NYSE:BMY) announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 ...
In localized non-small cell lung cancer (NSCLC), a tumor's ability to use carbon from glucose to feed the tricarboxylic acid ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...
The global lung cancer surgery market is poised for transformative growth from 2025 to 2035, driven by the increasing ...
An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...
John Ryan, a U.S. Navy veteran, beat cancer through nearly a decade of experimental immunotherapy treatment. The vet shared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback